Chemoimmunotherapy Vs Standard Care in ESCC: Is One Better?
Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard chemoradiotherapy in patients with locally advanced ESCC.
Medscape Medical News
source https://www.medscape.com/viewarticle/chemoimmunotherapy-vs-standard-chemoradiotherapy-escc-one-2025a100076g?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/chemoimmunotherapy-vs-standard-chemoradiotherapy-escc-one-2025a100076g?src=rss
Comments
Post a Comment